SEC Comment Letter 0000000000-23-004688 to Phio Pharmaceuticals Corp. (PHIO)
Phio Pharmaceuticals Corp.
Date: May 5, 2023 · CIK: 0001533040 · Accession: 0000000000-23-004688
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-271521
Letter
United States securities and exchange commission logo May 5, 2023 Robert Bitterman Chief Executive Officer Phio Pharmaceuticals Corp. 257 Simarano Drive, Suite 101 Marlborough, MA 01752 Re:Phio Pharmaceuticals Corp. Registration Statement on Form S-1 Filed April 28, 2023 File No. 333-271521 Dear Robert Bitterman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Steven Abrams, Esq.
Show Raw Text
United States securities and exchange commission logo
May 5, 2023
Robert Bitterman
Chief Executive Officer
Phio Pharmaceuticals Corp.
257 Simarano Drive, Suite 101
Marlborough, MA 01752
Re:Phio Pharmaceuticals Corp.
Registration Statement on Form S-1
Filed April 28, 2023
File No. 333-271521
Dear Robert Bitterman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Steven Abrams, Esq.